** Orion ORNBV.HE shares slip around 4% despite outlook
hike, with an analyst pointing to likely profit taking after the
Finnish drugmaker's strong share price run this year
** "As Orion shares have developed well and as 2025 outlook
looks weaker on reported basis ... the announcement seems to
trigger some profit taking," Danske Bank's Sami Sarkamies says
** Up to the previous session's close, shares were up 23%
YTD
** Jefferies notes feedback that Street numbers were already
known and calls the share price reaction as "overdone"
** Analysts also note a general weakness in pharmaceutical
sector, with STOXX healthcare index .SXDP down 0.1%
(Reporting by Anna Chaberska)
((Anna.chaberska@thomsonreuters.com))